Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

NCT07566156 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer
Urinary Bladder Neoplasms

Interventions

DRUG: Enfortumab vedotin
RADIATION: Conventional Radiotherapy
RADIATION: Hypofractionated Radiotherapy
DRUG: Cisplatin
DRUG: Fluorouracil
DRUG: Mitomycin C
DRUG: Gemcitabine
DRUG: Pembrolizumab

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]